GuidelinePediatric nephrology (Berlin, Germany)2006
Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines.
Guideline in Pediatric nephrology (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01479088 (Twelve-month, Multicenter, Intra-subject Controlled), which is not on this map. Cited by 60 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension.
Who cites it
60 citing papers in PubMed, 4 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease.Nature reviews. Nephrology · 2019Guideline
- Interventions for metabolic bone disease in children with chronic kidney disease.The Cochrane database of systematic reviews · 2015Pooled it
- Clinical practice recommendations for the care of infants with stage 5 chronic kidney disease (CKD5).Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.Pediatric nephrology (Berlin, Germany) · 2011Guideline
- Efficacy and safety of sevelamer carbonate in hyperphosphatemic pediatric patients with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Trial
- The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial.Clinical journal of the American Society of Nephrology : CJASN · 2013Trial
- Middle-term use of Cinacalcet in paediatric dialysis patients.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-Mineral and Bone Disorder (Version 2024).Kidney international reports · 2026Article
- Executive Summary of Evidence-Based Guidelines for the Diagnosis and Treatment of Pediatric CKD-Mineral and Bone Disorder (Version 2024).Kidney international reports · 2026Article
- Growth Failure Associated With Parathyroid Hormone Levels in Pediatric Dialysis Patients: A Nationwide Cohort Study.Kidney medicine · 2026Article
- Bone Disease in CKD in Children.Calcified tissue international · 2021Review
- A retrospective study of end-stage kidney disease patients on maintenance hemodialysis with renal osteodystrophy-associated fragility fractures.BMC nephrology · 2021Article
- Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.Calcified tissue international · 2021Review
- CKD-MBD post kidney transplantation.Pediatric nephrology (Berlin, Germany) · 2021Article
- Enteral Ca-Intake May Be Low and Affects Serum-PTH-Levels in Pre-school Children With Chronic Kidney Disease.Frontiers in pediatrics · 2021Article
- Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.Pediatric nephrology (Berlin, Germany) · 2020Review
- Treatment of hyperphosphatemia: the dangers of high PTH levels.Pediatric nephrology (Berlin, Germany) · 2020Review
- Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.Pediatric nephrology (Berlin, Germany) · 2020Article
- Management of bone disease in cystinosis: Statement from an international conference.Journal of inherited metabolic disease · 2019Article
- Factors and Outcome of Renal Osteodystrophy-Associated Initial Fragility Fracture in End-Stage Renal Disease Patients.Kidney diseases (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 13 institutions in 12 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood renal osteodystrophy (ROD) is the consequence of disturbances of the calcium-regulating hormones vitamin D and parathyroid hormone (PTH) as well as of the somatotroph hormone axis associated with local modulation of bone and growth cartilage function. The resulting growth retardation and the potentially rapid onset of ROD in children are different from ROD in adults. The biochemical changes of ROD as well as its prevention and treatment affect calcium and phosphorus homeostasis and are directly associated with the development of cardiovascular disease in pediatric renal patients. The aims of the clinical and biochemical surveillance of pediatric patients with CRF or on dialysis are prevention of hyperphosphatemia, avoidance of hypercalcemia and keeping the calcium phosphorus product below 5 mmol(2)/l(2). The PTH levels should be within the normal range in chronic renal failure (CRF) and up to 2-3 times the upper limit of normal levels in dialysed children. Prevention of ROD is expected to result in improved growth and less vascular calcification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.